Preferred Medications
- Humalog® (insulin lispro [rDNA origin] injection)
- Humalog® 50/50 mix (50% insulin lispro protamine suspension/ 50% insulin lispro [rDNA origin] injection)
- Humalog® Mix 75/25 (75% insulin lispro protamine suspension/ 25% insulin lispro [rDNA origin] injection)

Non-Preferred Medications
- Apidra® (insulin glulisine [rDNA origin] injection)
- NovoLog® (insulin aspart [rDNA origin] injection)
- NovoLog Mix 70/30 (70% insulin aspart protamine suspension/ 30% insulin aspart [rDNA origin] injection)

Overview
Apidra, Humalog, and NovoLog are rapid acting insulin analogs indicated for the treatment of patients (adults and children) with diabetes to control hyperglycemia. Generally, the rapid-acting insulin analogs should be used in combination with a longer-acting insulin.

Policy Statement
A step therapy program has been developed to encourage the use of a Humalog product prior to the use of an Apidra or Novolog product. If the preferred step therapy rule is not met for a non-preferred agent at the point of service, coverage will be determined by the preferred step therapy criteria below. All approvals are provided for 1 year in duration.

Automation: Patients with a history of one Step 1 drug within the 130-day look-back period are excluded from step therapy.

Step 1: Humalog vials, Humalog cartridges, Humalog prefilled insulin device (KwikPen), Humalog 50/50 mix vials, Humalog 50/50 mix prefilled insulin device (KwikPen), Humalog 75/25 mix vials, Humalog 75/25 mix prefilled insulin device (KwikPen).

Step 2: Apidra vials, Apidra SoloStar prefilled pen, NovoLog vials, NovoLog PenFill® cartridges, NovoLog FlexPen®, Novolog 70/30 mix vials and Novolog 70/30 mix FlexPen.
PREFERRED STEP THERAPY CRITERIA

1. If a patient has tried a Step 1 product approve a Step 2 product.

REFERENCES